title: Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1.
abstract: OBJECTIVE
  The characteristics and natural history of the paclitaxel-acute pain syndrome (P-APS) and paclitaxel's more chronic neuropathy have not been well delineated.
  
  
  METHODS
  Patients receiving weekly paclitaxel (70 to 90 mg/m(2)) completed daily questionnaires and weekly European Organisation for Research and Treatment of Cancer (EORTC) Chemotherapy-Induced Peripheral Neuropathy (CIPN) -20 instruments during the entire course of therapy.
  
  
  RESULTS
  P-APS symptoms peaked 3 days after chemotherapy. Twenty percent of patients had pain scores of 5 to 10 of 10 with the first dose of paclitaxel. Sensory neuropathy symptoms were more prominent than were motor or autonomic neuropathy symptoms. Of the sensory neuropathy symptoms, numbness and tingling were more prominent than was shooting or burning pain. Patients with higher P-APS pain scores with the first dose of paclitaxel appeared to have more chronic neuropathy.
  
  
  CONCLUSIONS
  These data support that the P-APS is related to nerve pathology as opposed to being arthralgias and/or myalgias. Numbness and tingling are more prominent chronic neuropathic symptoms than is shooting or burning pain.
authors.affiliation: Department of Oncology, Mayo Clinic, 200 First St, SW, Rochester, MN 55905, USA. cloprinzi@mayo.edu
authors.forename: Charles L
authors.initials: CL
authors.lastname: Loprinzi
authors.forename: Brandi N
authors.initials: BN
authors.lastname: Reeves
authors.forename: Shaker R
authors.initials: SR
authors.lastname: Dakhil
authors.forename: Jeff A
authors.initials: JA
authors.lastname: Sloan
authors.forename: Sherry L
authors.initials: SL
authors.lastname: Wolf
authors.forename: Kelli N
authors.initials: KN
authors.lastname: Burger
authors.forename: Arif
authors.initials: A
authors.lastname: Kamal
authors.forename: Nguyet A
authors.initials: NA
authors.lastname: Le-Lindqwister
authors.forename: Gamini S
authors.initials: GS
authors.lastname: Soori
authors.forename: Anthony J
authors.initials: AJ
authors.lastname: Jaslowski
authors.forename: Paul J
authors.initials: PJ
authors.lastname: Novotny
authors.forename: Daniel H
authors.initials: DH
authors.lastname: Lachance
mesh_terms: D000208:Acute Disease; D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects*; D019540:Area Under Curve; D016009:Chi-Square Distribution; D005260:Female; D006801:Humans; D008875:Middle Aged; D017239:Paclitaxel / Q000009:adverse effects*; D010146:Pain / Q000139:chemically induced*; D010147:Pain Measurement; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced*; D011446:Prospective Studies; D018709:Statistics, Nonparametric; D011795:Surveys and Questionnaires; D013577:Syndrome
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel